» Articles » PMID: 32580186

Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma

Overview
Publisher Karger
Specialties Endocrinology
Neurology
Date 2020 Jun 25
PMID 32580186
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Craniopharyngiomas (CP) are rare brain tumors managed primarily with surgery and radiotherapy. There are 2 phenotypes of CP, i.e., one with a rather good outcome without hypothalamic damage and another with hypothalamic damage. With hypothalamic damage, progressive disease with recurrent operations and additional cranial radiotherapy often result in hypothalamic obesity, an affected psychosocial life, and cognitive dysfunction. The morbidity and mortality are increased for particularly cerebrovascular diseases. Preoperative hypothalamic involvement to predict hypothalamic damage is important for decision making for hypothalamus-sparing surgery. Also a postoperative hypothalamic damage evaluation with the use of hypothalamus volume measurement can predict hypothalamic obesity, which is important for early treatment options. The morbidity of CP includes cognitive dysfunction with attention deficits and impaired episodic memory and processing speed. Again patients with hypothalamic damage are more affected. Treatment options of hypothalamic obesity in the chronic phase are scarce and not convincingly successful. The most optimal situation is to try to hinder or stop the evolution of hypothalamic obesity. Prevention of hypothalamic damage is recommended, with special regard to hypothalamus-sparing therapeutic approaches that respect the integrity of essential nuclei located in both the medial and the posterior hypothalamic areas.

Citing Articles

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma.

Erfurth E, Siesjo P, Sundgren P, Hammar B, Kinhult S Endocr Oncol. 2025; 4(1):e240024.

PMID: 39822776 PMC: 11737518. DOI: 10.1530/EO-24-0024.


Endocrine sequelae after pediatric craniopharyngioma treatment: a single-center retrospective cohort study.

Papy M, Jacobs S, Rochtus A J Pediatr Endocrinol Metab. 2024; 37(11):954-961.

PMID: 39428970 DOI: 10.1515/jpem-2024-0275.


Integrated Microbiome and Metabolome Analysis Reveals Hypothalamic-Comorbidities Related Signatures in Craniopharyngioma.

Lin B, Ye Z, Cao Z, Ye Z, Yu Y, Jiang W Adv Sci (Weinh). 2024; 11(39):e2400684.

PMID: 39225628 PMC: 11497089. DOI: 10.1002/advs.202400684.


A Histopathological Journey Through Adamantinomatous Craniopharyngioma: A Case Report.

Girepunje A, Hiwale K, Agrawal A, Naseri S, Paramba T Cureus. 2024; 16(8):e65917.

PMID: 39221395 PMC: 11364980. DOI: 10.7759/cureus.65917.


Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic-Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview.

Calandrelli R, DApolito G, Martucci M, Giordano C, Schiarelli C, Marziali G Cancers (Basel). 2024; 16(14).

PMID: 39061172 PMC: 11275213. DOI: 10.3390/cancers16142532.


References
1.
Olson I, Von Der Heide R, Alm K, Vyas G . Development of the uncinate fasciculus: Implications for theory and developmental disorders. Dev Cogn Neurosci. 2015; 14:50-61. PMC: 4795006. DOI: 10.1016/j.dcn.2015.06.003. View

2.
Secher A, Jelsing J, Baquero A, Hecksher-Sorensen J, Cowley M, Dalboge L . The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124(10):4473-88. PMC: 4215190. DOI: 10.1172/JCI75276. View

3.
Koenig K, Sakaie K, Lowe M, Lin J, Stone L, Bermel R . The relationship between cognitive function and high-resolution diffusion tensor MRI of the cingulum bundle in multiple sclerosis. Mult Scler. 2015; 21(14):1794-801. PMC: 4661103. DOI: 10.1177/1352458515576983. View

4.
Pereira A, Schmid E, Schutte P, Voormolen J, Biermasz N, van Thiel S . High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf). 2005; 62(2):197-204. DOI: 10.1111/j.1365-2265.2004.02196.x. View

5.
Prieto R, Pascual J, Rosdolsky M, Castro-Dufourny I, Carrasco R, Strauss S . Craniopharyngioma adherence: a comprehensive topographical categorization and outcome-related risk stratification model based on the methodical examination of 500 tumors. Neurosurg Focus. 2016; 41(6):E13. DOI: 10.3171/2016.9.FOCUS16304. View